NOT-CA-24-079: Notice of Expiration of PAR-24-117 "The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional)"

Notice of Expiration of PAR-24-117 "The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional)"

Notice Number:

NOT-CA-24-079

Key Dates

Release Date:

July 9, 2024

Related Announcements

July 03, 2024 - Notice of Intent to Publish a Funding Opportunity Announcement for NCI Pathway to Independence Award (K99/R00 – Independent Clinical Trial Optional). See NOT-CA-24-077.
February 09, 2024 - The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional). See PAR-24-117.

Issued by

National Cancer Institute (NCI)

Purpose

This Notice is to inform the research community of the early expiration of PAR-24-117 "The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional)" effective November 13, 2025. Instead, the National Cancer Institute intends to issue a Notice of Funding Opportunity (NOFO) for the NCI Pathway to Independence Award (K99/R00 - Independent Clinical Trial optional) that makes significant changes to the NIH Pathway to Independence Award (Parent K99/R00), including expanding the K99 eligibility window from 4 to 6 years of postgraduation research training experience (NOT-CA-24-077). Potential K22 candidates could consider submitting an application in response to the new NCI K99/R00 NOFO for which they may be eligible.

Inquiries

Please direct all inquiries to:

Sonia B. Jakowlew, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5630
Email: jakowles@mail.nih.gov